Pioneering prostate cancer therapy could stop thousands of men needing surgery
The technology 'fuses' an MRI (magnetic resonance imaging) scanner with ultrasound to identify diseased cells. A precisely targeted laser fibre is then heated up to annihilate them.
ConclusionsRetrograde release of the neurovascular bundle with preservation of dorsal venous complex during RARP is safe and associated with excellent oncological and functional outcomes. Future comparative studies are needed.Patient summaryRobot-assisted radical prostatectomy (RARP) presents consistent oncological outcomes for prostate cancer; yet continence and potency results are not uniform. We present a technical modification for RARP aiming to preserve the nerves and vascular structures anterior to the prostate. We evaluated 128 consecutive patients with clinically localized or locally advanced prostate cancer underg...
Publication date: Available online 20 July 2018Source: European UrologyAuthor(s): Felix Preisser, Elio Mazzone, Sebastiano Nazzani, Marco Bandini, Zhe Tian, Michele Marchioni, Thomas Steuber, Fred Saad, Francesco Montorsi, Shahrokh F. Shariat, Hartwig Huland, Markus Graefen, Derya Tilki, Pierre I. KarakiewiczAbstractCytoreductive radical prostatectomy (CRP) may offer a survival advantage, according to several retrospective analyses. However, few data are available regarding the morbidity of radical prostatectomy in the metastatic setting. We addressed intra- and postoperative complications of CRP relative to radical prosta...
Publication date: Available online 20 July 2018Source: European UrologyAuthor(s): Ilaria Cavarretta, Nicasio Mancini, Andrea Salonia
CONCLUSIONS: eRARP is a safe, reproducible, and effective procedure for the surgical treatment of prostate cancer. Superior functional outcome can be achieved when a bilateral intrafascial nerve-sparing approach can be performed. PMID: 30021425 [PubMed - as supplied by publisher]
ConclusionPIRADS ≥ 3 had high specificity and high negative predictive value for csPCa using biopsy results as the standard of reference. The presence of csPCa from a biopsy site was highly unlikely in the absence of a corresponding PIRADS ≥ 3 nodule.
Nicholas J. Vogelzang, MD, shares his thoughts on imaging as an effective solution for prostate cancer diagnosis at ASCO 2018. Author: obr Added: 07/20/2018
Nicholas J. Vogelzang, MD, talks about how MRI has improved the diagnosis of prostate cancer at ASCO 2018. Author: obr Added: 07/20/2018
Nicholas J. Vogelzang, MD, explains explains how to avoid under-diagnosing &over-diagnosing prostate cancer at ASCO 2018. Author: obr Added: 07/20/2018
Condition: Prostate Cancer Intervention: Diagnostic Test: 18F-DCFPyL IV injection Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Not yet recruiting